Cybin CEO to Discuss Psychedelic Mental Health Therapies at Growth Conference

Cybin Inc., a leader in the development of next-generation mental health treatments, has announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Scheduled for August 12, 2025, in Boston, this event will spotlight Cybin's pioneering work in neuropsychiatry, particularly its development of psychedelic-based therapies for mental health conditions. The presentation, which will be webcast live at 2:30 p.m. ET, offers investors and the public a closer look at Cybin's clinical-stage compounds, CYB003 and CYB004.

These proprietary molecules are being studied for their potential to treat major depressive disorder and generalized anxiety disorder, respectively. With mental health conditions affecting millions worldwide, Cybin's research represents a significant step forward in addressing a critical unmet need in healthcare. The company's approach focuses on intermittent treatments that promise long-lasting results, a departure from traditional daily medications. This innovative strategy could revolutionize the treatment landscape for mental health disorders, offering hope to those for whom current therapies fall short.

Cybin's commitment to advancing psychedelic science is evident in its robust pipeline of investigational compounds targeting 5-HT receptors, which play a key role in mood regulation. The archived webcast of the fireside chat will be accessible through Cybin's investor relations site at https://www.cybin.com/investors, providing ongoing access to this important discussion on the future of mental health treatment. The participation of Cybin's CEO at the Canaccord Genuity Growth Conference underscores the growing recognition of psychedelic-based therapies as a viable and promising avenue for mental health treatment.

As the company continues to advance its clinical programs, the potential for these treatments to make a meaningful difference in the lives of individuals suffering from mental health conditions becomes increasingly tangible. Additional information about Cybin's groundbreaking work is available on the company's website at https://www.cybin.com. The development of these novel therapies represents an important advancement in mental healthcare, potentially offering new options for patients who have not responded to conventional treatments.